Celltrion/Pfizer Agree To Wait For Mid-September Inflectra Launch

09 Jun 2016

• By Donna Young

Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar Inflectra (infliximab-dyyb) pending an ongoing legal dispute, have agreed to wait a little bit longer – now until after Sept. 15 under a stipulation with Janssen Biotech Inc., whose monoclonal antibody Remicade was the innovator on which the copycat was referenced.

Under a stipulation, Korean firm Celltrion Inc. and its partner New York pharma mammoth Pfizer Inc. have agreed not to launch their biosimilar Inflectra (infliximab-dyyb) until after Sept. 15, absent certain conditions.

Janssen Biotech Inc., a subsidiary of Johnson & Johnson, whose drug Remicade (infliximab) was the reference on which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins

05 Jun 2025

• By Mandy Jackson

Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

05 Jun 2025

• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.